HomeCompareRMED vs JNJ

RMED vs JNJ: Dividend Comparison 2026

RMED yields 336.70% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RMED wins by $3337.80M in total portfolio value
10 years
RMED
RMED
● Live price
336.70%
Share price
$0.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3337.83M
Annual income
$2,106,889,629.77
Full RMED calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — RMED vs JNJ

📍 RMED pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRMEDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RMED + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RMED pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RMED
Annual income on $10K today (after 15% tax)
$28,619.53/yr
After 10yr DRIP, annual income (after tax)
$1,790,856,185.30/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, RMED beats the other by $1,790,852,199.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RMED + JNJ for your $10,000?

RMED: 50%JNJ: 50%
100% JNJ50/50100% RMED
Portfolio after 10yr
$1668.93M
Annual income
$1,053,447,159.59/yr
Blended yield
63.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RMED
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Altman Z
-31.7
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RMED buys
0
JNJ buys
0
No recent congressional trades found for RMED or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRMEDJNJ
Forward yield336.70%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$3337.83M$30.3K
Annual income after 10y$2,106,889,629.77$4,689.40
Total dividends collected$3218.78M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: RMED vs JNJ ($10,000, DRIP)

YearRMED PortfolioRMED Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$44,370$33,670.03$10,592$272.30+$33.8KRMED
2$187,097$139,620.61$11,289$357.73+$175.8KRMED
3$750,420$550,226.83$12,123$472.89+$738.3KRMED
4$2,865,463$2,062,513.01$13,141$629.86+$2.85MRMED
5$10,426,475$7,360,429.85$14,408$846.81+$10.41MRMED
6$36,186,404$25,030,075.51$16,021$1,151.60+$36.17MRMED
7$119,906,417$81,186,964.99$18,122$1,588.22+$119.89MRMED
8$379,719,698$251,419,831.96$20,930$2,228.20+$379.70MRMED
9$1,150,408,903$744,108,826.12$24,792$3,191.91+$1150.38MRMED
10$3,337,827,156$2,106,889,629.77$30,274$4,689.40+$3337.80MRMED

RMED vs JNJ: Complete Analysis 2026

RMEDStock

Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.

Full RMED Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RMED vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RMED vs SCHDRMED vs JEPIRMED vs ORMED vs KORMED vs MAINRMED vs ABBVRMED vs MRKRMED vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.